What are the risks of combined sitagliptin and dapagliflozin in type 2 diabetes patients?
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901897466609664 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | The combination of sitagliptin and dapagliflozin for type 2 diabetes management appears to have a favorable safety profile, with studies indicating general tolerability and no significant new safety issues. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17705620 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | What are the risks of combined sitagliptin and dapagliflozin in type 2 diabetes patients? Tripdatabase risks combined sitagliptin dapagliflozin type diabetes patients The combination of sitagliptin and dapagliflozin for type 2 diabetes management appears to have a favorable safety profile, with studies indicating general tolerability and no significant new safety issues. |
| title | What are the risks of combined sitagliptin and dapagliflozin in type 2 diabetes patients? |
| topic | risks combined sitagliptin dapagliflozin type diabetes patients |
| url | https://doi.org/10.5281/zenodo.17705620 |